ClinicalTrials.gov
public full text
Public Domain
Oral Androgens in Man-4: (Short Title: Oral T-4)
The protocol was designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism#829905
- Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH#1060546
- TRADE-Testosterone Replacement and Dutasteride Effectiveness#968981
- Hormonal Associations in Male Patients With Psoriasis Vulgaris#1185288
- To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone#1463043
Record · ID 1464260
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive